Multi-omics profiling reveals CDKN2A mutant early-onset lung squamous cell carcinoma with a “hot” tumor immune microenvironment

Our study identifies <i>CDKN2A</i> mutation as a hallmark of a unique, aggressive yet immunogenic subtype of early-onset LUSC. This association appears to be specific to young patients, highlighting age of onset as a key biological variable. These findings provide a rationale for further investigation of <i>CDKN2A</i> status as a potential biomarker to guide immunotherapy strategies in early-onset LUSC.